BPC-157 and TB-500 for patellar tendinitis: what the evidence says

What did @shewygetsfit actually say?

She tried BPC-157 and TB-500 for roughly two years of patellar tendinitis in both knees and concluded they did nothing meaningful. Her exact words: "I don't think it's done anything." She did offer one small caveat, saying the peptides "kind of helped my shoulder out a little bit," which is actually an important detail she almost throws away. Her main verdict is that neither peptide helped with swelling, inflammation, or the underlying tendon issue, and she advises others with chronic patellar tendinitis to "probably stay away."

This is an honest n=1 report from someone with genuine frustration, not a bad-faith takedown. But personal experience, even well-documented personal experience, is not the same as evidence. The fact that it did not work for her in this specific context does not mean these peptides are inert across all injury types.

Does the science back this up?

The honest answer is: the science on these peptides is thin, mostly preclinical, and nowhere near conclusive enough to guarantee results in chronic human tendinopathy. So her skepticism is justified, even if her framing slightly overgeneralizes.

BPC-157 has shown pro-angiogenic and tendon-fibroblast-stimulating effects in rat tendon injury models (Staresinic et al., 2003, Journal of Orthopaedic Research), but the leap from a rat Achilles transection to a two-year-old human patellar tendinopathy is enormous. Chronic tendinopathy, sometimes called tendinosis at this stage, involves degenerative collagen disorganization, not just acute inflammation. A peptide that accelerates healing in fresh wounds may have little traction in a tissue that has already remodeled poorly over years.

TB-500, a synthetic fragment of thymosin beta-4, also shows wound-healing and actin-regulation activity in animal models (Goldstein et al., 2012, Annals of the New York Academy of Sciences), but there are no peer-reviewed human clinical trials for tendon injuries. None. That gap matters enormously.

What did they get wrong (or right)?

She got the big picture right: these are not proven treatments for chronic patellar tendinitis in humans. Calling them a potential "expensive gimmick" in her situation is a reasonable conclusion given the evidence gap. She deserves credit for noting that the shoulder response was different, which actually aligns with the preclinical idea that acute or subacute injuries may respond differently than chronic degenerative ones.

What she gets slightly wrong is generalizing her outcome to everyone with patellar tendinitis. The line "I probably stay away" is reasonable personal advice but gets amplified on TikTok into a categorical claim. Dosing protocol, injection route, product quality, and injury stage all vary significantly. Subcutaneous or oral administration, as is common in most self-reported peptide use, delivers very different bioavailability than the intra-tendon or peritendinous injections used in animal studies.

She also does not mention whether she used a medical provider, what dosing protocol she followed, or the source and quality of her peptides. Compounded peptides vary in purity and concentration, and that matters for any biological effect.

What should you actually know?

Patellar tendinopathy that has persisted for two or more years is a genuinely hard clinical problem. Even well-studied interventions like heavy slow resistance training, which has the strongest evidence base for chronic tendinopathy (Rio et al., 2015, British Journal of Sports Medicine), require months of consistency and often produce only partial relief. The idea that a peptide injection cycle fixes two years of tendon degeneration in a short window is biologically optimistic at best.

The peptide space is currently operating well ahead of its clinical evidence. That does not make these compounds useless, but it does mean anyone using them should have realistic expectations, particularly for chronic degenerative conditions rather than acute injuries. If you are considering BPC-157 or TB-500 for a tendon issue, a conversation with a licensed provider who understands the current evidence limitations is the starting point, not a TikTok recommendation in either direction.

• Chronic patellar tendinopathy involves structural collagen changes that may not respond the same way acute injuries do.
• Peptide quality and administration route can meaningfully affect whether any biological activity occurs at the injury site.
• No peptide has regulatory approval for tendon injury treatment in humans as of 2024.